STAT3 and cancer: However, the JAK/STAT3 pathway, as the most well-known IL-6 downstream pathway, remains controversial until Huang et al. claimed that JAK/STAT3, in combination with other downstream IL-6 pathways, frequently and significantly promoted IL-6 autocrine through a positive feedback loop in a wide range of cancer cell lines and clinical samples [33].